There are several different types of pemphigus. The two main forms are pemphigus vulgaris and pemphigus foliaceus, which affect different layers of the outermost layer of the skin (epidermis) and have different symptoms. The epidermis serves as a protective barrier and consists of five different layers. Pemphigus vulgaris affects the deeper layers; pemphigus foliaceus affects the outermost layer.
The blisters that occur in pemphigus may be referred to as flaccid bullae because they are not firm and break open (rupture) easily. Individuals with pemphigus vulgaris generally feel ill. I; individuals with pemphigus foliaceus often only have crusted rather than blistering lesions because the lesions are too high in the epidermis to retain fluid. Both forms of pemphigus can be associated with itching.
Pemphigus can be controlled with treatment. If left untreated, serious life-threatening complications such as the loss of most of the epidermis can occur. Widespread involvement of the skin can also lead to severe infections of the skin, which can potentially spread to the bloodstream (sepsis) or imbalances of fluids or certain minerals (electrolytes) in the body. These imbalances can interfere with various essential chemical processes in the body. Prior to the introduction of effective therapy, most patients with pemphigus died within two years.
The most common form of pemphigus in the United States is pemphigus vulgaris. Affected individuals usually develop irregularly-shaped, painful erosions or lesions (ulcerations) of the mucous membranes lining the inside of the mouth (oral cavity). Blisters rarely form because they rupture almost immediately leaving multiple, superficial, ulcerated sores throughout the mouth. The mucous membranes lining the inside of the cheeks (buccal mucosa), the lips, the roof of the mouth (palate) and the tongue are most often affected. These lesions can join together so that large, raw sores affect the mouth. These lesions are slow to heal and may make it difficult to eat or drink.
Anywhere from a few weeks to months following the onset of mucous membrane involvement, blistering (bullous) lesions eventually develop on the skin. The scalp, face, neck and upper parts of the chest and back are most often the initial sites affected. The lesions of pemphigus vulgaris form in the deep layers of the epidermis and may be painful. The lesions may ooze clear fluid or bleed. As these lesions heal, they may become dry and crusty. Although they do not scar, they usually heal with treatment and rarely leave discolored or darkened patches of skin.
Additional areas of the skin that are frequently affected include the armpits and groin. Additional mucous membranes that are affected include the ones found in the nose (nasal mucosa), genitals, and lining the inside of the eyelids (conjunctiva). The throat and esophagus may also become affected. Involvement of the nasal mucosa may cause a stuffy nose and frequent discharge of bloody mucous. Involvement of the throat may cause hoarseness, difficulty swallowing and pain when swallowing.
A distinct finding called the Nikolsky sign is associated with pemphigus vulgaris. The Nikolsky sign refers to areas of normal looking skin in which the top part of the skin separates (peels off) from the underlying layer of skin when slight pressure is applied (e.g., slightly rubbed or pinched).
This form of pemphigus is characterized by multiple small, blisters or crusted lesions that quickly break apart to form itchy (pruritic), scaly, crusted lesions. Because the blisters form on the uppermost layer of the epidermis, they may break apart so quickly that only the ensuing crusted lesions are noticed. The lesions may also have a reddened (erythematous) base and can be painful or associated with a burning sensation. The scalp, face, chest and back are most often affected. Unlike pemphigus vulgaris, little to no involvement of the mucous membranes occurs.
Individuals with pemphigus foliaceus exhibit the Nikolsky sign, which describes areas of normal looking skin in which the top part of the skin separates (peels off) from the underlying layer of skin when slight pressure is applied (e.g., slightly rubbed or pinched).
In some cases, the lesions associated with pemphigus foliaceus may disappear on their own without treatment (spontaneous remission). In many cases, however, the lesions gradually increase in number over weeks and months. In severe cases, the lesions may spread, eventually coming together to resemble exfoliative erythroderma, a condition characterized by widespread red and scaly lesions that can cover large portions of the body.
In some cases, degenerative (atrophic) changes of the hair and nails may also occur.
Endemic pemphigus (fogo selvagum)
This form of pemphigus foliaceus occurs in a disproportionally large number of individuals (epidemically) in South America, especially rural areas of Brazil. It also occurs in other rural areas of the world. The symptoms of endemic pemphigus are identical to those described above for pemphigus foliaceus. This form of pemphigus often runs in families, which suggests that genetic or environmental factors play a significant role in the development of endemic pemphigus.
Pemphigus erythematosus (Senear-Usher syndrome)
This form of pemphigus is characterized by initial lesions that are reddened (erythematous) and crusty and, although the symptoms of pemphigus foliaceus are present, affected individuals also have symptoms normally associated with lupus. The lesions of this form of pemphigus are most likely to appear in areas of the body where oil-producing glands (seborrheic glands) are found such as the cheeks, scalp and upper chest and back. Affected individuals may also have antibodies usually found in individuals with lupus.
This form of pemphigus is considered a variant of pemphigus vulgaris. It is characterized by lesions that most frequently affect the skin fold areas (flexures) such as the armpits or groin. The lesions of pemphigus vegetans differ from pemphigus vulgaris because they often become overgrown, thickened and warty.
This general term refers to pemphigus (either pemphigus vulgaris or pemphigus foliaceus) that develops due to the use of certain drugs. Although drug-induced pemphigus is an uncommon occurrence, it is important to distinguish pemphigus that occurs secondary to drug use because symptoms often disappear once the drug is stopped. Penicillamine and a class of drugs known as angiotensin-converting enzyme (ACE) inhibitors (e.g., captopril) are most commonly associated with the development of pemphigus. ACE inhibitors are often used to treat high blood pressure or heart failure. Penicillamine is used to treat different conditions including rheumatoid arthritis.
Pemphigus is a group of autoimmune disorders. Autoimmune disorders occur when the body’s immune system mistakenly attacks healthy tissue.
The immune system normally produces specialized proteins called antibodies. Antibodies react against foreign materials (e.g., bacteria, virus, toxins) in the body bringing about their destruction. Specific antibodies are created in response to specific a material or substance. A substance that stimulates an antibody to be produced is called an antigen. When antibodies react against healthy tissue, they are known as autoantibodies. There are five main classes of antibodies – IgA, IgD, IgE, IgG, and IgM. Pemphigus is due to IgG antibodies.
In pemphigus, autoantibodies react to antigens found on the surface of certain skin cells (keratinocytes). Keratinocytes are the major cell of the epidermis and they stick (adhere) together to form the barrier that is the epidermis. Keratinocytes are able to stick together because specialized proteins called desmogleins act as glue to hold them together. The autoantibodies in pemphigus target the desmogleins causing keratinocytes to lose their ability to stick together, resulting in the separation of these skins cells from one another and the breakdown of the affected skin cell layer (acantholysis). This leads to the blistering that characterizes pemphigus. The autoantibodies in pemphigus specifically react to certain desmogleins. In pemphigus vulgaris, the autoantibodies react against desmoglein-3 and in half the cases to desmoglein-1; in pemphigus foliaceus, they react only against desmoglein-1.
The exact reason why the immune system malfunctions in individuals with pemphigus is unknown. Researchers believe that some individuals may have a genetic predisposition to developing pemphigus. A person who is genetically predisposed to a disorder carries a gene (or genes) for the disease, but it may not be expressed unless it is triggered or “activated” under certain circumstances, such as due to particular environmental factors (multifactorial inheritance).
A variety of factors have been speculated to trigger or worsen pemphigus. Such factors include exposure to ultraviolent light, trauma to the skin, and possibly certain foods. Stress may also aggravate pemphigus. Certain drugs are also known to play a role in the development or aggravation of pemphigus.
Pemphigus affects males and females in equal numbers. It usually occurs in middle-aged individuals, usually people in their 50s and 60s. In rare cases, pemphigus can affect children. The overall incidence and prevalence of pemphigus varies depending upon the specific population studied. Pemphigus is estimated to affect anywhere from 0.7-5 people per 1,000,000 per year in the general population. Pemphigus vulgaris is the most common form of pemphigus and is the most common form in Europe and the United States. Pemphigus foliaceus is more prevalent in Africa and certain rural areas in the world. Endemic pemphigus is a specific form of pemphigus foliaceus that occurs in individuals in certain rural regions of South America, especially within Brazil and Colombia. Pemphigus vulgaris occurs with greater frequency in individuals of Jewish and Mediterranean descent.
A diagnosis of pemphigus is suspected based upon identification of characteristic findings, a thorough clinical evaluation, and a detailed patient history. A diagnosis must be confirmed based upon a variety of specialized tests including blood tests for antibodies that cause the disease and a skin biopsy that shows the typical histological changes associated with the disease. Blood tests can reveal the characteristic antibodies that cause the symptoms of pemphigus. A skin biopsy is a small sample of affected tissue that is taken and examined under a microscope, which may reveal characteristic separation of skin cells. Physicians may also perform direct immunofluorescence on a skin biopsy sample. This is a test in which the sample is stained with special dyes that allow antibodies to seen under a special microscope. Determining the specific antibody by an ELISA test confirms a diagnosis of pemphigus and distinguishes the specific forms of pemphigus from one another.
If signs suggest the involvement of the throat or nasal cavity, an ear-nose-throat (ENT) specialist may need to assess these areas to determine whether pemphigus is affecting the mucous membranes in these areas.
The treatment of pemphigus is directed toward suppressing the skin and mucosal lesions of the disease and preventing complications potentially associated with pemphigus or its treatment. Although there is no cure for pemphigus, the disorder can usually be controlled. Most patients will eventually enter a complete remission in which they are off all therapy and there is no evidence of the disease. Generally, the less widespread the pemphigus is, the easier it is to control.
The development, severity and progression of pemphigus are not uniform and the response to particular therapies can vary among individuals. Consequently, physicians will take several different factors into account when planning an individual’s treatment, which will be tailored to the individual’s specific needs and situation.
Treatment of pemphigus is usually separated into phases: control, consolidation and maintenance. In the control phase, high-intensity therapy is used to bring the disorder under control by initiating the healing of current lesions, reducing or suppressing new lesion formation, and improving other symptoms such as relieving itching. In the consolidation phase, a consistent dose of medication is used until a significant portion of lesions have healed. In the maintenance phase, the dose of medication is gradually reduced until a minimal level is achieved that is successful in preventing the development of new lesions.
The mainstay of treatment for pemphigus is the use of high doses of corticosteroids such as prednisone, which are anti-inflammatory medications that also suppress the effects of the immune system. Steroids may be applied directly to the affected areas (topically) or may be taken by mouth or given by injection (systemic steroids). Topical therapy is generally given to reduce pain and prevent or treat infection. Most individuals will receive systemic steroids to bring about control of pemphigus. The dose of steroids used can be lessened (tapered) if control of the disorder is achieved.
Other medications that may be used in combination with corticosteroids to treat individuals with pemphigus include drugs that suppress the immune system (immunosuppressive drugs) such as mycophenolate mofetil, azathioprine, methotrexate, or cyclophosphamide, methotrexate; drugs that modify or regulate the immune system (immunomodulatory drugs) such as IVIg, Rituximab, dapsone; or antibiotics such as doxycycline. These medications may be used to allow physicians to lower the overall dose of steroids. Rituximab therapy can be used as first-line therapy in patients with co-morbidities that make longer-term steroid therapy more difficult, and ongoing studies will determine its role earlier in therapy.
Some individuals respond to therapy quickly; others respond more slowly or do not respond at all. In severe cases or in cases where individuals fail to respond to other therapies, pulse steroids, plasmapheresis or intravenous immunoglobulin therapy (IVIG) may be used. Pulse steroid therapy refers to the administration of extremely high levels of steroids given for a short period of time. Plasmapheresis is a method for removing unwanted substances (e.g., autoantibodies) from the blood, and is not used as much now because of increased risk of infecctions. Blood is removed from the patient and blood cells are separated from plasma. The patient’s plasma is then replaced with other human plasma and the blood is transfused into the patient. For more information on IVIG therapy, see the investigational therapies section below.
Intravenous immunoglobulin (IVIG) therapy is being studied as a treatment for individuals with pemphigus. Initial research shows that this form of therapy may be an effective alternative for individuals who are unresponsive to conventional therapy, dependent upon corticosteroids, or experience adverse side effects to corticosteroids. Research has indicated that IVIG therapy can markedly decrease levels of the abnormal antibodies associated with pemphigus without decreasing the levels of normal, health antibodies. More research is necessary to determine the long-term safety and effectiveness of intravenous immunoglobulin therapy for individuals with pemphigus. IVIG is normally given with other therapy, such as steroids and immunosuppressives, to prevent rebound of disease as the therapy is tapered.
Researchers are studying rituximab for the treatment of individuals with pemphigus. This drug attacks the cells that produce the autoantibodies in pemphigus that damage the skin. Rituximab is classified as a monoclonal antibody or biologic therapy. More research is necessary to determine the long-term safety and effectiveness, as well as the timing, dose, and frequency of use of rituximab, for the treatment of individuals with pemphigus.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll-free: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
For information about clinical trials conducted in Europe, contact:
Bystryn JC. Pemphigus Vulgaris and Pemphigus Foliaceus. NORD Guide to Rare Disorders. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:132.
Murrell DF, Autoimmune Blistering Diseases. Dermatologic Clinics. Philadelphia, PA: Elsevier Health Sciences; 2011; 29: Volumes I and II.
Hertl M, Jedlickova H, Karpati S, Marinovic B, Uzun S, Yayli S, et al. Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015 Mar;29(3):405-14.
Murrell DF, Amagai M, Werth VP. Scoring systems for blistering diseases in practice: why bother, and which one should you use? JAMA Dermatol. 2014;50(3):245-7.
Shimizu T, Takebayashi T, Sato Y, Niizeki H, Aoyama Y, Kitajima Y, et al. Grading criteria for disease severity by pemphigus disease area index. J Dermatol. 2014 Nov;41(11):969-73.
Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64(5):903-8.
Schultz H, Diaz LA, Sirois D, Werth VP, Grando SA. Generating consensus research goals and treatment strategies for pemphigus and pemphigoid. Meeting Report. J Invest Dermatol. 2011;131(7):1395-9.
Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. JAmAcadDermatol. 2011;66(3):479-85.
Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol.2010;130(8):2041-8.
Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009(1):CD006263.
Rosenbach M, Murrell DF, Bystryn JC, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009;129(10):2404-10.
Paradisi A, Sampogna F, Di Pietro C, Cianchini G, Didona B, Ferri R, et al. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools. J Am Acad Dermatol. 2009;60(2):261-9.
Groves RW. Pemphigus: a brief review. Clin Med. 2009;9:371-375.
Joly P, Roujeau JC, Benichou J, Delaporte E, D’Incan M, Dreno B, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129(7):1681-7.
Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595-603.
Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043-6
Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol. 2008;58:796-801.
Pfutze M, Niedermeier A, Hertl M, Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol. 2007;17(1):4-11.
Joly P, Mouquet H, Roujeau JC, D’Incan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545-52.
Tron F, Gilbert D, Mouquet H, et al. Genetic factors in pemphigus. J Autoimmun. 2005:24:319-328.
Warren SJ, Lin MS, Guidice GJ. The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. N Engl J Med. 2000;343:23-30.
Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol.132(8):1998-2004.
Pemphigus. Mayo Clinic for Medical Education and Research. http://www.mayoclinic.com/health/pemphigus/DS00749 Updated November 7, 2012. Accessed May 11, 2015.
Pemphigus. National Institute of Arthritis and Musculoskeletal and Skin Diseases. http://www.niams.nih.gov/Health_Info/Pemphigus/default.asp Updated June 2013. Accessed May 11, 2015.